Original Article

Abortion Stigma as a Barrier to Mifepristone Use among Obstetrician-Gynecologists in Alabama for Early Pregnancy Loss

Authors: Mugdha Mokashi, MD, MPH, Christina Boulineaux, BS, Elizabeth Janiak, ScD, Margaret Boozer, MD, Sara Neill, MD, MPH

Abstract

Objectives: The objective of our study was to identify and characterize barriers to mifepristone use among obstetrician-gynecologists (OB-GYNs) for early pregnancy loss in a southern US state.

Methods: In this qualitative study, we conducted semistructured interviews with 19 OB-GYNs in Alabama who manage early pregnancy loss. The interviews explored participants’ knowledge of and experience with mifepristone use for miscarriage management and abortion, along with barriers to and facilitators of clinical mifepristone use. The interviews were coded by multiple study staff using inductive and deductive thematic coding.

Results: Nearly all of the interviewees identified abortion-related stigma as a barrier to mifepristone use. Interviewees often attributed stigma to a lack of knowledge about the clinical use of mifepristone for early pregnancy loss. The stigmatization of mifepristone due to its association with abortion was related to religious and political objections. Many interviewees also described stigma associated with misoprostol use. Although providers believed that mifepristone use for abortion would not be accepted in their practice, most believed that mifepristone could be used successfully for miscarriage management after practice-wide education on its use.

Conclusions: Mifepristone is strongly associated with abortion stigma among OB-GYNs in Alabama, which is a barrier to its use for miscarriage management. Interventions to decrease abortion stigma and associated stigma surrounding mifepristone are needed to optimize early pregnancy loss care.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Neill S. Management of early pregnancy loss. JAMA 2023;329:1399–1400.
 
2. Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med 2018;378: 2161–2170.
 
3. Sinha P, Suneja A, Guleria K, et al. Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: a randomized double-blind placebo-controlled trial. J Obstet Gynaecol India 2018;68:39–44.
 
4. Macnaughton H, Nothnagle M, Early J. Mifepristone and misoprostol for early pregnancy loss and medication abortion. Am Fam Physician 2021; 103:473–480.
 
5. Chu JJ, Devall AJ, Beeson LE, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet 2020;396: 770–778.
 
6. Berkley HH, Greene HL, Wittenberger MD. Mifepristone combination therapy compared with misoprostol monotherapy for the management of miscarriage: a cost-effectiveness analysis. Obstet Gynecol 2020;136:774–781.
 
7. Mifeprex REMS Study Group. Sixteen years of overregulation: time to unburden Mifeprex. N Engl J Med 2017;376:790–794.
 
8. Calloway D, Stulberg DB, Janiak E. Mifepristone restrictions and primary care: breaking the cycle of stigma through a learning collaborative model in the United States. Contraception 2021;104:24–28.
 
9. Boos EW, Horta M, Thompson I, et al. Trends in the use of mifepristone for medical management of early pregnancy loss from 2016 to 2020. JAMA 2023;330:766–768.
 
10. Neill S, Hoe E, Fortin J, et al. Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use. Contraception 2023;126:110108.
 
11. Srinivasulu S, Yavari R, Brubaker L, et al. US clinicians’ perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care. Contraception 2021;104:92–97.
 
12. Desai S, Jones RK, Castle K. Estimating abortion provision and abortion referrals among United States obstetrician-gynecologists in private practice. Contraception 2018;97:297–302.
 
13. Neill S, Mokashi M, Goldberg A, et al. Mifepristone use for early pregnancy loss: a qualitative study of barriers and facilitators among OB/GYNs in Massachusetts, USA. Perspect Sex Reprod Health 2023;55:210–217.
 
14. Neill S, Janiak E. Facilitators of and barriers to mifepristone use for early pregnancy loss among OB/GYNs: a qualitative study. Second Year Fellows Research Forum. Published online May 2020.
 
15. Smith W, Turan JM, White K, et al. Social norms and stigma regarding unintended pregnancy and pregnancy decisions: a qualitative study of young women in Alabama. Perspect Sex Reprod Health 2016;48: 73–81.
 
16. National Constitution Center. Supreme Court case. Dobbs v. Jackson Women’s Health Organization (2022). https://constitutioncenter.org/the-constitution/supreme-court-case-library/dobbs-v-jackson-womens-health-organization. Published 2022. Accessed May 16, 2024.
 
17. Vinekar K, Karlapudi A, Nathan L, et al. Projected implications of overturning Roe v Wade on abortion training in U.S. obstetrics and gynecology residency programs. Obstet Gynecol 2022;140:146–149.
 
18. Kirstein M, Dreweke J, Jones R, et al. 100 days post-Roe: at least 66 clinics across 15 US states have stopped offering abortion care. https://www.guttmacher.org/2022/10/100-days-post-roe-least-66-clinics-across-15-us-states-have-stopped-offering-abortion-care. Published October 6, 2022. Accessed March 18, 2023.
 
19. Flynn AN, Roe AH, Koelper N, et al. Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss. Contraception 2021;103:404–407.
 
20. Ehrnstén L, Altman D, Ljungblad A, et al. Efficacy of mifepristone and misoprostol for medical treatment of missed miscarriage in clinical practice —a cohort study. Acta Obstet Gynaecol Scand 2020;99:488–493.
 
21. Johnson DM, Ramaswamy S, Gomperts R. Experiences with misoprostolonly used for self-managed abortion and acquired from an online or retail pharmacy in the United States. Contraception 2023;131:110345.
 
22. Newton-Hoe E, Lee A, Fortin J, et al. Mifepristone use among obstetriciangynecologists in Massachusetts: prevalence and predictors of use. Womens Health Issues 2024;34:135–141.
 
23. Avery DM, Reed MD, Skinner CA. Re: family medicine and obstetrics: let’s stop pretending. J Am Board Fam Med 2019;32:279.
 
24. Roth GA, Fleszar LG, Bryant AS, et al. Trends in state-level maternal mortality by racial and ethnic group in the United States. JAMA 2023;330:52–61.